Financing will support the development of novel surfaceome-targeted therapies for hard-to-treat tumors ...

The Company’s IPO price was set at 26.68 RMB per share, with an opening price of 58 RMB, representing a 117% increase over ...

To register for the webcast, click here . A replay will be available on the Corbus website.

The MarketWatch News Department was not involved in the creation of this content. -- Collaboration leverages OBT's proprietary OGAP(R)-Verify platform and GSK's drug development expertise to advance ...

Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology ...